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Reply
We appreciate the interest of the readers above in our study
analyzing the association of statins with mortality after infraingui-
nal bypass in patients with critical limb ischemia. Their insightful
comments point to a weakness inherent to all nonrandomized
studies—propensity score models or multivariable regression mod-
els can only control for measured confounders and not unmea-
sured confounders. Our study did not control for cholesterol
levels, because these values were not available from our source data
(the PREVENT III trial).
While we agree with the readers that there is a small body of
literature, primarily pertaining to general surgery, that has sug-
gested a potential benefit to hypercholesterolemia, this effect has
yet to be demonstrated in patients with peripheral arterial disease.
Nonetheless, our data do not allow us to refute the comments of
the readers above—it is possible that, in our study, some of the
mortality benefit that was attributed to the use of statins may have
been affected by concurrent hypercholesterolemia in the patient
group on statin therapy.
Andres Schanzer, MD
Division of Vascular and Endovascular Surgery
University of Massachusetts Medical School
Worcester, Mass
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Carotid artery stenting: a promising therapeutic
option for carotid artery stenosis or a bubble about
to burst?
A recent prospective randomized trial compared for the first
time the long-term results of carotid endarterectomy (CEA) with
carotid artery stenting (CAS) (median observation time: 64 12.1
months vs. 66  12.1 months, respectively).1 This study showed
that CEA is superior to CAS with respect to stroke (0 of 42 vs. 4 of
42, respectively),70% restenosis (0 of 29 vs. 6 of 32, respectively)
and re-intervention rates (0 of 29 vs. 5 of 32, respectively; for all
associations P  .05).1
Two issues may hamper the interpretation of the results of this
study:1 first, CAS was performed without the use of embolic
protecting devices (EPDs).1 Although the exact role of EPDs in
CAS has not yet been established, their use may offer considerable
advantages. For example, a large (n  1,483 patients), multi-
center (n 26 hospitals), randomized study comparing CAS with
vs. without EPDs demonstrated that, compared with non-use, the
use of EPDs during CAS was associated with lower ipsilateralstroke (4.1% vs. 1.7%, respectively; P  .007) and lower non-fatal
stroke and death rates (4.9% vs. 2.1%, respectively; P  .004).2
Opposing results were reported in a recent prospective random-
ized study comparing the incidence of embolic lesions during CAS
with vs. without EPDs;3 the use of EPDs during CAS did not
reduce the number of emboli (average number of embolic lesions:
6.1 vs. 6.2, respectively; P  .79).3 A possible explanation for this
lack of difference may be the small size of CAS procedures included
(n  36).3
A second drawback is the early recruitment period (August
1999 to April 2002).1 Since then, the technique of CAS has
evolved considerably; new, better-designed, and improved stent
models have been introduced and employed. Additionally, physi-
cians have gradually become more experienced; a study presenting
a detailed analysis of periprocedural complications of CAS demon-
strated the importance of an appropriate learning curve before
systematic use of CAS.4 Thus, it could be expected that a similar
study performed today might produce different results than the
ones reported.1
The role of CAS in the treatment of carotid artery stenosis is
still the subject of extensive debate. Current evidence suggests that
it may still be premature to attempt to draw definite conclusions.
Kosmas I. Paraskevas, MD, FASA
Department of Vascular Surgery
“Red Cross” Hospital
Athens, Greece
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Reply
Thank you for the opportunity to respond to the letter con-
cerning our article “Alert for increased long-term follow-up after
carotid artery stenting: Results of a prospective, randomized, single-
center trial of carotid artery stenting vs carotid endarterectomy.”
Carotid endarterectomy (CEA) or carotid artery stenting
(CAS) in symptomatic patients is performed to reduce the risk of
secondary stroke or stroke-related death. Therefore, the main
focus of this article was the evaluation of restenosis, secondary
stroke rate, and death in a long-term follow-up of a prospective,
randomized study of CEA vs CAS.
We understand the concern that embolic protection devices
(EPD) might reduce peri-interventional stroke rates after CAS.
However, the cited publication1 is not a randomized study but
rather a registry from multiple cardiology centers during 1998 to
2003. The use of embolic protection devices (EPD) increased over
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cohort analysis. The decision to treat or not to treat was left to the
interventionist, who was not a neurologist. Along with other
methodologic drawbacks, such as only registration of the compli-
cation rate during the hospital stay, any conclusion in comparison
with our article should not be drawn.
The short-term results of our study revealed no difference
between CAS and CEA (one vs no stroke, Table III). Importantly,
however, there are no reports that EPDs are able to reduce
secondary stroke rates on the long term. There is strong evidence
that the reported stroke rates of four in 42 after CAS vs none in 42
after CEA in the long-term follow-up from our study correlate
with the higher incidence of restenosis, and not with whether
EDPs were used.
It is also notable that the study was performed in a high-
volume center in Germany with very experienced surgical and
interventional physicians. No residual stenosis was left after the
primary procedure, and the intervention was performed with a low
peri-interventional complication rate (Table III). An influence of a
learning curve can be excluded. We admit that the exclusive use of
the carotid Wallstent (Boston Scientific, Watertown, Mass) might
influence the results of this study. However, this was extensively
discussed in the second paragraph on page 97. Unfavorable results
of prospective randomized trials should not be questioned with a
remark that new devices might be more beneficial.
Most recent data of the SPACE (Stent-Supported Percutane-
ous Angioplasty of the Carotid Artery versus Endarterectomy)
study, which was randomized until February 2006 and used dif-
ferent and “better designed and improved” stent types, support
our findings. In the 1-year follow-up, a twofold higher restenosis
rate of8% was observed after CAS vs CEA (Prof. Dr. H. Eckstein,
personal communication). These data confirm our conclusion that
CEA seems to be superior to CAS concerning the development of
restenosis and that ongoing trials have to gather long-term data
including restenosis and reintervention rates as well as secondary
stroke rates and survival.
Markus G.M. Steinbauer, MD
Piotr M. Kasprzak, MD
Vascular and Endovascular Surgery
University of Regensburg
Regensburg, Germany
Felix Schlachetzki, MD
Department of Neurology
University of Regensburg
Regensburg, Germany
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Regarding “Easy alternatives to difficult clamping of
distal vessels of the leg”
We have read with great interest the paper by August et al.
Actually, the use of ordinary clamps can result in arterial damage,
especially in endstage renal disease (ESRD) patients affected by
critical limb ischemia (CLI).
Our group performed more than 1500 open distal arterial
reconstructions of tibial and pedal arteries in CLI patients with
tissue loss and gangrene (Rutherford 5-6). We used autologous
material in 92% of grafts, preferably greater saphenous vein, fol-
lowed by lesser saphenous and arm veins.1,2 Comorbidities werediabetes 56%, clinically apparent coronary artery disease (CAD)
47%, previous aorto-coronary bypass graft (CABG) 8%, chronic
obstructive pulmonary disease (COPD) 57%, chronic renal insuf-
ficiency 20%, and ESRD 10.4%.3
Finally, 164 limbs in ESRD patients with CLI were revascu-
larized. The majority of these patients had a very diseased distal
arterial network with heavily calcified arteries, poor run-off, and
relevant comorbidities. Consequently, bypasses were more distal
and technically demanding if compared to the standard CLI pa-
tients.3 In our experience, as in others, renal insufficiency entailed
a worse limb salvage (P  .048), and ESRD has been associated
with significantly worse limb salvage (P  .001) and patient
survival (P  .011).4-6
In this kind of patient, often distal arteries are not compress-
ible due to extensive wall calcification.
For several years, by performing distal anastomosis, we have
been putting a clamp only on the proximal part of the target vessel
and we have been applying, as August et al, an intravenous cannula
in order to occlude the distal end of the arteriotomy in tibial and
plantar vessels. On the contrary to the authors, we did not cut the
top of the cannula, but we did connect it by a 20-cm long plastic
tube to a 30-mL syringe filled with heparinated (.20%) saline
(Fig 1). The length of the tube has been useful to not hinder the
suturing maneuvers. The whole system allowed a regular flushing
with heparinated saline into the distal runoff, preventing throm-
bosis of the lumen in cases of poor retrograde bleeding. The size of
cannulas varied between 18G and 24G according to the lumen of
the artery.
Despite the caliber adaptation, in few cases it was not possible
to move the cannula forward into the artery, because of the
irregularity of the arterial wall. In these situations, we chose to
clamp the artery only proximally to the arteriotomy, as we do in all
cases, but not to clamp it distally at all. In order to minimize blood
loss, we positioned the patient in an extreme Trendelenburg
position, with the head raised to avoid discomfort, and we clamped
the distal artery by gentle external digital compression (Fig 2). If
the digital occlusion was ineffective due to stiffness of the arterial
wall, we simply flushed the anastomosis area by pouring saline that
flowed away with the blood thanks to the upraised position of the
limb.
In conclusion, even though we agree with August et al about
the advantage of the use of an intravenous cannula for distal arterial
occlusion, we suggest the artifices we use since they critically
Fig 1. Intravenous cannula has been inserted into the plantar
artery. The cannula has been connected to a syringe with hepari-
nated solution.
